Jump to main content
Jump to site search

Issue 18, 2017
Previous Article Next Article

TRAIL–NP hybrids for cancer therapy: a review

Author affiliations


Cancer is a worldwide health problem. It is now considered as a leading cause of morbidity and mortality in developed countries. In the last few decades, considerable progress has been made in anti-cancer therapies, allowing the cure of patients suffering from this disease, or at least helping to prolong their lives. Several cancers, such as those of the lung and pancreas, are still devastating in the absence of therapeutic options. In the early 90s, TRAIL (Tumor Necrosis Factor-related apoptosis-inducing ligand), a cytokine belonging to the TNF superfamily, attracted major interest in oncology owing to its selective anti-tumor properties. Clinical trials using soluble TRAIL or antibodies targeting the two main agonist receptors (TRAIL-R1 and TRAIL-R2) have, however, failed to demonstrate their efficacy in the clinic. TRAIL is expressed on the surface of natural killer or CD8+ T activated cells and contributes to tumor surveillance. Nanoparticles functionalized with TRAIL mimic membrane-TRAIL and exhibit stronger antitumoral properties than soluble TRAIL or TRAIL receptor agonist antibodies. This review provides an update on the association and the use of nanoparticles associated with TRAIL for cancer therapy.

Graphical abstract: TRAIL–NP hybrids for cancer therapy: a review

Back to tab navigation

Publication details

The article was received on 28 Feb 2017, accepted on 29 Mar 2017 and first published on 04 Apr 2017

Article type: Review Article
DOI: 10.1039/C7NR01469D
Nanoscale, 2017,9, 5755-5768

  •   Request permissions

    TRAIL–NP hybrids for cancer therapy: a review

    H. Belkahla, G. Herlem, F. Picaud, T. Gharbi, M. Hémadi, S. Ammar and O. Micheau, Nanoscale, 2017, 9, 5755
    DOI: 10.1039/C7NR01469D

Search articles by author